【摘要】 目的观察拉米夫定和(或)阿德福韦酯治疗失代偿期乙型肝炎肝硬化3年疗效。方法收集乙型肝炎肝硬化失代偿期患者68例,分为抗病毒治疗组和对照组,观察入组患者的临床症状、体征、生化指标、HBV DNA和Child-Pugh分级等变化情况。结果随访治疗中,治疗组6个月后ALT、ALB和HBV DNA水平均较对照组有明显改善,12个月后TBil和Child-Pugh评分较对照组有明显改善,差异具有统计学意义(P<0.05);治疗组和对照组36个月生存率分别为62.5%和36.1%,差异具有统计学意义(P<0.05);36个月后治疗组和对照组肝细胞癌发生率分别为3.1%和8.3%,差异无统计学意义。结论拉米夫定和(或)阿德福韦酯治疗失代偿期乙型肝炎肝硬化,能够改善患者肝功能,延缓疾病进展,提高生存率。更多还原

【Abstract】 Objective To determine the clinical therapeutic effect of 3-year treatment by lamivudine and/or adefovir dipivoxil on patients with liver cirrhosis following chronic hepatitis B.Methods Total of 68 cases of hepatitis B patients with liver cirrhosis were divided into anti-viral treatment group and control group.Clinical manifestations,biochemical indicators,HBV DNA loads and Child-Pugh classification were recorded.Results After following-up for 6,12,24,36 months,the levels of ALT,ALB,HBV DNA loads after 6 months and TBil,Child-Pugh classification after 12 months of anti-viral treatment group improved significantly compared with control group(P< 0.05).There were singnificant differences in the survival rates for 3 years which was 62.5% of anti-viral treatment group compared with 36.1% of control group(P< 0.05).There was no singnificant difference in the incidence rates of hepatocellular carcinoma for 3 years which was 3.1% of anti-viral treatment group compared with 8.3% of control group.Conclusions Lamivudine and/or adefovir dipivoxil were effective for the treatment of patients with liver cirrhosis following chronic hepatitis B virus infection.更多还原